Medium-Chain Triglycerides

Summary

Medium-Chain Triglycerides (CHEMBL4298042) is a phase-3 clinical-stage unknown.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Clinical trials: 6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4298042
Name	Medium-Chain Triglycerides
Type	Unknown
Max phase	3

Also known as: Caprylic/capric triglyceride, Medium-chain triglycerides, Miglyol 810 n, Miglyol 812 n, Neobee 1053, MEDIUM-CHAIN TRIGLYCERIDES

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
Not specified	4
PHASE3	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01595893	PHASE3	TERMINATED	Vitamin D Supplementation in Polymorphic Light Eruption
NCT01252979	EARLY_PHASE1	COMPLETED	Ketones & Mitochondrial Heteroplasmy
NCT01806142	Not specified	COMPLETED	Effects of Medium-Chain Triglycerides on Chylomicron Secretion and Expression of Genes That Regulate Intestinal Lipid Metabolism in Men With Dyslipidemia Associated With the Metabolic Syndrome
NCT02199821	Not specified	COMPLETED	Inflammatory Response With Different Lipid Emulsions In Parenteral Nutrition In Children After Bone Marrow Transplantation
NCT05779410	Not specified	COMPLETED	Vitamin D in Healthy Adults After Strenuous Endurance Exercise
NCT05781620	Not specified	UNKNOWN	Vitamin D Supplementation in Healthy Adults in Prolonged Endurance Exercise

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).